Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Stock Market Commentary: Trump Signals a Major Drop in Oil Prices. Will U.S. Stocks Surge?
US Open: Nasdaq tries to recover loses 🗽 Fair Isaac shares in panic
Wall Street: Does the S&P 500 Still Have Room to Rise?
AMD Goes Shopping: Is Its $8.2 Billion Investment a Good Move?